Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

20260 citationsJournal Articlehybrid Open Access

Authors

Yee Hui Yeo · Cedars-Sinai Medical Center

Sepideh Mehravar · Cedars-Sinai Medical Center

Ellen Choi · Englewood Hospital and Medical Center

Julie Yang · Cedars-Sinai Medical Center

Hyun‐seok Kim · Cedars-Sinai Medical Center

Y. Wang · Cedars-Sinai Medical Center

Aarshi Vipani

Abstract

In this large real-world study, baclofen was associated with a higher risk of hepatic encephalopathy compared with acamprosate in patients with compensated alcohol-associated cirrhosis.

Topics & Keywords

Alcohol Consumption and Health Effects Liver Disease and Transplantation Alcoholism and Thiamine Deficiency

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Alimentary Pharmacology & Therapeutics

DOI: 10.1111/apt.70619

Field-Weighted Citation Impact: 0.00